Is anti-Müllerian hormone associated with IVF outcomes in young patients with diminished ovarian reserve?

20Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: To investigate whether anti-Müllerian hormone (AMH) is associated with IVF cycle outcomes in young patients with diminished ovarian reserve. Materials & methods: Retrospective study of patients <35 years of age undergoing fresh IVF who had at least two 8-cell, day-3 embryos transferred with grades 1, 1.5 or 2. Patients were subgrouped, a priori, based on serum AMH levels: <1 or >1 ng/ml and <0.5 or >0.5 ng/ml. Results: In total, 1005 patients were included. Patients in the >1 ng/ml group required lesser gonadotropins compared with the <1 ng/ml and the <0.5 ng/ml group. More oocytes were retrieved from the same group compared with the latter two (p < 0.001). Despite these differences, the overall rates of clinical pregnancy, spontaneous abortion and live birth were comparable between the two groups. Conclusion: In patients with diminished ovarian reserve who have good quality embryos, AMH is not associated with clinical pregnancy, spontaneous miscarriage or live birth rates.

Cite

CITATION STYLE

APA

Pereira, N., Setton, R., Petrini, A. C., Lekovich, J. P., Elias, R. T., & Spandorfer, S. D. (2016). Is anti-Müllerian hormone associated with IVF outcomes in young patients with diminished ovarian reserve? Women’s Health, 12(2), 185–192. https://doi.org/10.2217/whe.15.102

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free